Harnessing Innate Immunity Against Glioblastoma Microenvironment

Strategic Insights -

Researchers at Xinxiang Medical University in Kaifeng, People's Republic of China, have shed light on the pivotal role of innate immunity in glioblastoma (GBM) pathogenesis. The study reviews the current understanding of innate immune mechanisms in GBM and explores novel combinatorial strategies to overcome therapeutic resistance in this lethal malignancy. By targeting innate immunity, researchers aim to reshape the immunosuppressive tumor microenvironment (TME) and restore effective immune responses against glioblastoma.

Key Takeaways:

  • The tumor microenvironment (TME) in glioblastoma (GBM) is dominated by innate immune mechanisms, including tumor-associated macrophages (TAMs), microglia, and myeloid-derived suppressor cells (MDSCs).
  • These innate immune cells facilitate immune evasion and impair adaptive T-cell responses, limiting the efficacy of current immunotherapies.
  • Emerging evidence highlights the therapeutic potential of targeting innate immunity via TAM repolarization, MDSC depletion, and NK cell activation.
  • Novel combinatorial strategies that integrate innate immune modulation with checkpoint blockade, oncolytic virotherapy, and metabolic interventions may offer a promising approach to overcoming therapeutic resistance in GBM.
  • Wenbo Zhang, Department of Neurology, Kaifeng Central Hospital, Xinxiang Medical University, Kaifeng, People's Republic of China, is leading this research effort, which includes additional authors Wanhong Zhang, Henghao Wu, Xinsheng Han.
  • This review aims to provide a comprehensive understanding of the role of innate immunity in GBM and to explore innovative therapeutic strategies to combat this aggressive malignancy.

Statistics:

  • 16% of glioblastoma cases are attributed to genetic mutations in the IDH1 gene.
  • Glioblastoma is the most devastating form of primary brain cancer, accounting for approximately 30% of central nervous system tumors.
  • Checkpoint blockade therapy has shown limited efficacy in glioblastoma due to immune evasion mechanisms.
  • Oncolytic virotherapy has demonstrated potential in glioblastoma treatment by targeting the tumor microenvironment.
  • Metabolic interventions, such as targeting the Warburg effect, have been explored as a means to control tumor growth and restore immune function.

Sources:

  • Frontiers in Immunology. (2025,16). Harnessing innate immunity against glioblastoma microenvironment. https://doi-org.sdpl.idm.oclc.org/10.3389/fimmu.2025.1648601
  • Immunotherapy Weekly. (2025, August 13). Research on Cancer Gene Therapy Described by Researchers at Xinxiang Medical University (Harnessing innate immunity against glioblastoma microenvironment). p 79.